Blogs

Oncology drugs pose significant challenges in packaging due to their potency, toxicity, and the risks of human and environmental contamination. Ensuring sterility is crucial for certain administration methods, while also safeguarding against potential harm to handlers and manufacturers. Improper packaging or material selection can result in weak seals, breaches in sterility, and product leakage, compromising both safety and efficacy.

Early-stage package development and ongoing in-process packaging checks are essential measures to guarantee effective packaging. While various tests like Extractables and Leachables (E&L) and Transportation tests contribute to product safety, they may not always detect leaks in packaging. Therefore, Container Closure Integrity Testing (CCIT) emerges as a robust and indispensable method for identifying poor packaging performance and guiding package development.

CCIT offers a comprehensive approach to assessing package integrity across a range of formats commonly used for oncology drugs, including rigid parenterals, bottles, IV bags, and blister packs. Each packaging format presents unique challenges, and CCIT offers tailored test methods for each, ensuring thorough evaluation and reliable results.

Blister packs, often utilized for oncology drugs, typically consist of a low headspace formed poly or foil tray with a flexible lid stock. For products packaged in aluminum cold form blisters, helium leak detection is employed for ultra-high sensitivity, capable of detecting leaks down to 1E-10 mBar/l*s. Additionally, force decay testing provides inline applications with sensitivity down to 15 microns, ensuring stringent quality control measures.

Rigid parenterals, another common packaging option, offer flexibility in testing methods, including Vacuum Decay and MicroCurrent High Voltage Leak Detection (HVLD). These methods can detect leaks down to 1 micron, both inline and offline, providing comprehensive assurance of package integrity.

In conclusion, addressing the unique packaging challenges of oncology drugs requires a multifaceted approach, with CCIT playing a pivotal role in ensuring product safety, efficacy, and regulatory compliance. By leveraging advanced testing methodologies tailored to specific packaging formats, manufacturers can mitigate risks and uphold the highest standards of quality assurance in oncology drug packaging.